IL 17s

Question 1

What are the PBS listed IL17s in Aus?

Answer 1

Ixekinumab (taltz)
Secukinumab (Cosentyx)
Bimekizumab (Bimzelx)

Question 2

How does Bimekizumab differ from secukinumab and ixekinumab?

Answer 2

Bime targets IL 17 A and F, secukinumab only targets IL 17 A

Question 3

What is cosentyx?

Answer 3

Secukinumab, an IL 17 (IL17A) inhibitor

Question 4

What is Bimzelx?

Answer 4

Bimekizumab, and IL 71 A and Il 17 F blocker

Question 5

What is Taltz?

Answer 5

Ixekinumab, IL 17 A inhibitor

Question 6

What are the C/I to IL 17s

Answer 6

Known hypersensitivity

Relative:
- chronic/recurrent infections
- inflammatory bowel disease

Question 7

What are the main side effects ass with IL 17?

Answer 7

Hypersensitivity reactions - anaphylaxis, urticaria, angiooedema

Nasopharyngitis / URTI

Mucocutaneous candidiasis

Neutropaenia (1 -2% of patients)

new onset or exacerbation of crohns / UC

Question 8

Dose of Ixekinumab

Answer 8

Taltz - S/C injection
160mg loading dose
Then 80mg every 2 weeks for 12 weeks
Then every 4 weeks

Question 9

What is the dosing schedule for Secukinumab?

Answer 9

Cosentyx - s/c injections
300mg at week 0, 1, 2, 3, 4, and then 4 weekly

Question 10

How quickly do IL 17s work

Answer 10

90% improvement by 12 weeks

Question 11

Patients with joint disease - what is the prefered biologic?

Answer 11

IL 17 or TNF inhibitor